Citations

Clear

2960 citation(s) found for "Kim, P".

Family History and Solar Insolation in Bipolar I Disorder
Bauer, M., Glenn, Tasha , Achtyes, E. D., Alda, M., Ağaoğlu, Esen , Altınbaş, Kürşat , Andreassen, O. A., Angelopoulos, E., Ardau, R., Aydin, Mehmet Zeki , Ayhan, Y., Baethge, Christopher , Bauer, Rita, Baune, B. T., Balaban, Ceylan, Becerra‐Palars, Claudia, Behere, A. P., Belete, Habte , Belete, Tilahun, Belizario, G. Okawa, Bellivier, F., Belmaker, R. H., Benedetti, F., Berk, M., Bersudsky, Y., Bicakci, Ş., Birabwa‐Oketcho, Harriet , Bjella, T. D., Brady, Conan , Cabrera, Jorge , Cappucciati, Marco , Castro, A. M. Paredes, Chen, W., Cheung, E. Y. W., Chiesa, S., Chanopoulou, Margarita, Cuomo, A., Dodd, S., Etain, B., Fagiolini, A., Fellendorf, F. T., Ferensztajn‐Rochowiak, Ewa , Fiedorowicz, J. G., Fountoulakis, K. N., Frye, M. A., Geoffroy, P. A., Gitlin, M. J., Gottlieb, J. F., Grof, Paul , Haarman, B.C.M., Harima, Hirohiko, Hasse‐Sousa, M., Henry, C., Hoffding, L., Houenou, J., Imbesi, M., Isometsä, E. T., Janno, Sven , Johnsen, S., Karakatsoulis, G. N., Kardell, Mathias, Kessing, L. V., Kim, S. J., Kot, T. L., Koval, M., Lafer, B., Landén, M., Larsen, E. R., Licht, R. W., Ludwig, V. M., Mackenzie, Alan, Madsen, H. Østergaard, Madsen, S. Alberte Kongstad A., Mahadevan, J., Mahardika, Agustine , Mahfoudh, K. Ben, Manchia, M., Marsh, W., Martiny, Klaus , Mashima, Y., McLoughlin, D. M., Meesters, A. N. R., Meesters, Ybe , Melle, I., Meza‐Urzúa, F., Michaelis, Elisabeth, Mok, Y. Ming, Monteith, Scott , Moorthy, Muthukumaran, Morken, G., Mosca, Enrica, Mozzhegorov, A. A., Munoz, R., Mythri, S. V., Nadella, R. K., Nakanotani, Takako, Nielsen, R. Ernst, O'Donovan, C., Omrani, Adel, Osher, Yamima , Pantovic‐Stefanovic, M., Pariwatcharakul, Pornjira, Petite, Joanne, Pilhatsch, M., Ruiz, Y. Pica, Pinna, M., Pompili, M., Porter, R., Quiroz, Danilo , Rabelo‐da‐Ponte, F. Diego, Ramesar, Raj , Rasgon, NL, Redahan, Maria, Reddy, M. S., Reif, A., Reininghaus, E. Z., Richards, J. Gringer, Rybakowski, J. K., Sathyaputri, Leela, Scippa, A. M., Simhandl, Christian , Smith, D., Smith, J., Stackhouse, P. W., Stein, D. J., Stilwell, Kellen, Su, K.‐P., Sulaiman, A. Hatim, Suominen, Kirsi, Tanra, A. J., Tatebayashi, Yoshitaka , Teh, W. Lin, Tondo, L., Torrent, C., Tuinstra, Daniel, Uchida, Takahito, Vaaler, A. E., Vieta, E., Viswanath, B., Volf, C., Yang, K‐J, Yalcinkaya, O. Kaan, Young, A. H., Zgueb, Yosra , Whybrow, P. C., Houenou, Josselin , Isometsä, Erkki , Licht, Rasmus Wentzer , Manchia, Mirko , Nielsen, René Ernst , Stein, Dan J. , Kessing, Lars Vedel , Young, Allan H. , Achtyes, Eric D. , Belete, T , Berk, Michael , Crowe, M , Fagiolini, Andrea , Frye, Mark , Grof, P , Kessing, L V , Kim, S J , Manchia, Mirko , McLoughlin, D M , Nadella, R K , Ouali, U , Pariwatcharakul, P , Pompili, M , Porter, R , Ritter, P , Rybakowski, Janusz K , Stein, Dan J , Strejilevich, S , Subramaniam, M , Vaaler, A E , Vieta, E , Yoldi-Negrete, M , Young, Allan H , Bauer, M., Alda, Martin , Altınbaş, Kürşat , Andreassen, Ole A. , Angelopoulos, Elias, Ardau, Raffaella , Aydin, M., Ayhan, Yavuz , Behere, Aniruddh Prakash, Belizário, Gabriel Okawa , Bellivier, Frank , Belmaker, Robert H. , Benedetti, Francesco , Berk, Michael , Bıçakcı, Şule , Bjella, Thomas , Castro, Angela Marianne Paredes , Cuomo, Alessandro, Dallaspezia, Sara , Desai, Pratikkumar Vrajeshbhai , Dodd, Seetal , Étain, Bruno , Fagiolini, Andrea , Fellendorf, F.T., Fiedorowicz, Jess G. , Fountoulakis, Konstantinos Ν. , Frye, Mark A. , Geoffroy, Pierre A. , Gitlin, Michael , González‐Pinto, Ana , Haarman, Bartholomeus C. M. , Hasse-Sousa, Mathias , Henry, Chantal , Høffding, Lone, Imbesi, Massimiliano, Ivković, Maja , Johnsen, Søren Paaske , Kapczinski, Flávio , Karakatsoulis, Grigorios N. , König, Barbara , Kunz, Maurício , Lafer, Beny , Landén, Mikael , Ludwig, Vera Miriam , López‐Jaramillo, Carlos , MacKenzie, A., Madsen, Helle Østergaard , Mahfoudh, K., Marsh, W., Martínez‐Cengotitabengoa, Mónica , Martini, Julia , Mashima, Yuki , Meesters, Alie N.R., Melle, Ingrid , Meza-Urzúa, Fátima, Mikoláš, Pavol , Mok, Yee Ming , Morken, Gunnar , Mozzhegorov, Anton A., Mythri, SV, C, O'Donovan, Ouali, Uta , Stefanovic, M. Pantovic, Pfennig, Andrea , Ruiz, Yolanda Pica, Pinna, Marco , Rabelo-Da-Ponte, F.D., Rasgon, Natalie , Ratta‐apha, Woraphat , Redahan, Maria, Reif, A., Reininghaus, EZ, Ritter, Philipp , Strejilevich, Sergio , Suominen, Kirsi, Teh, Wen Lin , Torrent, C., Vieta, Eduard , Viswanath, Biju , Yoldi‐Negrete, María , Young, A.H., Whybrow, Peter C.

Mayo Clinic

Acta Psychiatrica Scandinavica | March 8, 2026 | Volume: 153 | Issue: 4 | Pages: 270-278

10.1111/acps.70075 | PMID 41734899 Get It

ABSTRACT Background Sunlight has profound impacts on physical and mental health, beyond vision, including effects on circadian rhythms, alertness, mood, and sleep. A family history of any mood disorders is strongly associated with psychiatric disorders including bipolar disorder. The purpose of this study was to evaluate the association between a family history of any mood disorder in patients with bipolar I disorder and solar insolation at varied international onset locations. Methods Data for this analysis were available from 5842 patients with a diagnosis of bipolar I disorder obtained at 83 collection sites in both hemispheres. This included 4752 patients from 71 collection sites in the northern hemisphere and 1090 patients from 12 collection sites in the southern hemisphere. Patient data variables were obtained from records or interviews. Solar insolation data were obtained from The National Aeronautics and Space Administration (NASA) Power database for each onset location, and the ratio of the mean monthly minimum/mean monthly maximum solar insolation was calculated. Typically, the ratio is largest near the equator (little yearly change in solar insolation) and smallest near the poles (large yearly change in solar insolation). Results A significant relationship was found between a family history of any mood disorder, the ratio of the mean monthly minimum/mean monthly maximum solar insolation, and gender. The odds of a family history of mood disorder increased as patient location nears the poles and decreased near the equator. Female gender also increased the odds of having a family history of a mood disorder. Conclusions This study highlighted the association between family history, solar insolation, and gender in international patients with bipolar I disorder. Given the profound effects of sunlight on human health, the family of patients with bipolar disorder who live in the same location with the same solar insolation, and especially females, may be at increased risk for a mood disorder.
Gene Portals: A Framework for Integrating Clinical, Functional, and Structural Evidence into Rare Disease Variant Classification
Brünger, Tobias , Krey, Ilona , Kim, Suyeon, Klöckner, Chiara , Myers, Scott J, Johannesen, Katrine M. , Stefanski, Arthur , Taylor, Gary, Macnee, Marie , Dahl, Rebekka S., Yuan, Hongjie, Kim, Sukhan, Helbig, Ingo, Pan, Jen, Kurganov, Erkin , Baez, David, Zuberi, Sameer M., Lerche, Holger, May, Patrick, Ivaniuk, Alina, Meskis, Mary Anne , Hood, Veronica , Schust, Leah F., Freed, Amber, Froelich, Steven, Deng, Alexander T., Bouman, Arjan , Hajianpour, M.J. , Pal, Deb K. , Danvoye, Leslie, Lederer, Damien , BALCI, TUĞÇE, Hagebeuk, Eveline , Heidlebaugh, Alexis R. , Oetjens, Kathryn F., Striano, Pasquale, Williams, Sarah Drewes, Engelen, Kalene van , Howell, Katherine B. , Khoury, Jean , Benke, Tim A., Strehlow, Vincent , Platzer, Konrad, Ramsey, Amy J, Manaster, Lisa, Malepati, Sunitha, Fox, Pangkong M., Noebels, Jeffrey, Chung, Wendy, Poduri, Annapurna, Stripe, Laina Lusk, Ruggiero, Sarah M., Cohen, Stacey, Wilmarth, Olivia, Prentice, Anna Jenne, Cha, Esther, Budnik, Nikita , Kramer, Audra A. , Gh, Zhang, Palotie, Aarno, Daly, Mark J., Møller, R., Lemke, Johannes R., Lal, Dennis , Møller, Rikke S. , May, Patrick , Bruenger, Tobias , Pan, Jen Q , Farrant, Mark , Wyllie, David J A , Bosselmann, Christian , Mantegazza, Massimo , May, Patrick , Ivaniuk, Alina , Goodspeed, Kimberly , Trinidad, Marena , Aledo-Serrano, Ángel , Pal, Deb K , Platzer, Konrad , Ruggiero, Sarah M , Daly, Mark J. , George, Alfred L , Brunklaus, Andreas , Møller, Rikke S , Myers, Scott J. , Taylor, Gary, Pérez‐Palma, Eduardo , Schorge, Stéphanie , Dahl, Rebekka S. , Perszyk, Riley E. , Bajaj, Sunanjay , Helbig, Ingo , Wollmuth, Lonnie P. , Báez-Nieto, David , Zuberi, Sameer M. , Boßelmann, Christian M. , Mantegazza, Massimo , Cestèle, Sandrine , Ivaniuk, Alina , Kang, Jing‐Qiong , Gati, Cornelius , Montanucci, Ludovica , Wüster, Arthur , Deng, Alexander T. , Borovikov, Artem O. , Sharkov, Artem A. , Bouman, Arjan , Hoffman, Trevor L. , Howell, Katherine B. , Benke, Tim A. , Platzer, Konrad , Ramsey, Amy J. , Fox, Pangkong , Noebels, Jeffrey L. , Chung, Wendy K. , Poduri, Annapurna , Lusk, Laina G. , Cohen, Stacey , Smith, Lacey A. , Boesch, Sylvia , Prentice, Anna Jenne , Hommersom, Marina P. , Vanoye, Carlos G. , Nothnagel, Michael , Palotie, Aarno V. , George, Alfred L. , Zárate, Yuri A. , Brunklaus, Andreas , Traynelis, Stephen F. , Lemke, Johannes R.

Mayo Clinic

No container title available | March 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.05.26347086 | PMID 41822692 Get It

Abstract Rare Mendelian disorders affect 300-400 million people globally. Although genetic testing has become widely adopted, gene-specific evidence for tailored variant interpretation remains scattered across resources. We present Gene Portals, a framework for gene-centered multimodal knowledge bases that co-localize expert-harmonized clinical data, functional assays, population variation, structural annotations and gene-specific ACMG/AMP specifications within a single resource. A modular interface integrates this unified evidence with VCEP-refined ACMG specifications to enable automated gene-specific variant classification, infer molecular mechanisms, and support cross-gene analyses. We demonstrate the framework’s utility across five Gene portals spanning eleven neurodevelopmental disorder-associated genes, integrating data from 4,423 individuals with 2,838 unique variants, 36,149 ClinVar submissions, and 1,044 expert-curated molecular readouts. By organizing evidence that is otherwise dispersed across multiple sources into a unified, queryable framework, the SCN, GRIN, CACNA1A, SATB2 and SLC6A1 Gene Portals became widely used community resources and provide an extensible template for standardized rare-disease variant interpretation and mechanism-aware discovery.
Miniprotein inhibitors of the Staphylococcus aureus efflux transporter NorA
Mishra, Priyanka, Chazin-Gray, Adam, Lamon, Gaëlle , Kim, David E. , Baker, David, Traaseth, Nathaniel J. , Kim, David , Chazin-Gray, Adam M. , Baker, David

Mayo Clinic

No container title available | March 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.05.709893 | PMID 41847033 Get It

Abstract Multidrug efflux pumps transport antibiotics across the cellular membrane resulting in resistance conferred to the host organism. Efflux pump inhibitors (EPIs) potentiate the efficacy of antibiotics by blocking drug efflux and hold promise as adjuvant therapeutics in the fight against multidrug resistant pathogenic bacteria. A hurdle in the field has been the lack of selectivity of small molecule EPIs which often display off-target toxicity due to non-specific binding. To tackle this specificity challenge, we aimed to maximize an inhibitor’s binding surface area to efflux pumps by designing miniprotein EPIs using computational protein design and an E. coli co-expression assay to screen inhibition in cells. We used S. aureus NorA as a model efflux transporter since it confers drug resistance to fluoroquinolones, puromycin, and other cytotoxic compounds. Starting from a focused miniprotein library of only 86 members, we identified inhibitors in the screen that blocked NorA transport under active efflux conditions in vitro . Our most promising inhibitor I-23 was validated by solving a cryo-EM structure of the miniprotein in complex with NorA, which stabilized the transporter in the outward-open conformation. I-23 has a ferredoxin-like fold with one of its β-hairpins inserted into the substrate binding pocket of NorA and other parts of the globular fold occupying the shallow pocket and making extensive intermolecular contacts with NorA. An arginine residue on the tip of the hairpin loop was positioned near an anionic patch required for NorA antibiotic efflux. The identified structural motifs in this work could be employed to explore the molecular properties of peptidoglycan penetration; full realization of the therapeutic potential of the designed miniprotein inhibitors will require determining the principles for facilitating passage of ∼7 to 8 kDa miniproteins across the peptidoglycan bacterial cell wall.
Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections
Mackow, Natalie , Shao, Wanying, Ge, Lizhao , Komarow, Lauren, Jiang, Jianping , Boutzoukas, Angelique , Chen, Liang , Herc, Erica, Doi, Yohei, Arias, Cesar A, Jacob, J, Satlin, Michael J. , Huskins, W Charles, Dhar, Sorabh, Shelburne, Samuel A, Hill, Carol, Sadler, Jacob M., Hill, Bravada M, Greenwood-Quaintance, Kerryl E, Schmidt-Malan, Suzannah M., Patel, Robin, Fowler, Vance G, Tamma, Pranita D, Kreiswirth, Barry N, Group, for the Antibacterial Resistance Leadership, Chambers, Chip, Evans, Scott, Hamasaki, Toshi, Cross, Heather, Harris, Anthony, Pettigrew, Melinda M. , Duin, David van, Boucher, Helen , Dixon, Dennis O., Ghazaryan, Varduhi , Zou, Lanling, Raterman, Erica, Samuel, Tamika, Moon, Kyung, Hanson, Kim, Holland, Thomas, Lodise, Tom, Shelburne, Sam, Banerjee, Ritu, Cosgrove, Sara, Paterson, David, Lautenbach, Ebbing , Mehigan, Maureen, Doernberg, Sarah, Doi, Yohei , Chen, Liang , Boutzoukas, Angelique E , Jiang, Jianping , Doi, Yohei , Albin, Owen , Saade, Elie , Miller, Loren G , Jacob, Jesse T , Satlin, Michael J , Krsak, Martin , Huskins, W Charles , Shelburne, Samuel A , Hill, Carol , Alby, Kevin , Sadler, Jacob M , Hill, Bravada M , Patel, Robin , Fowler, Vance G. , Tamma, Pranita D , van Duin, David , Pettigrew, M M , Evans, Scott R , Ge, Lizhao , Komarow, Lauren , Garcia‐Diaz, Julia , Herc, Erica , Arias, César A. , Albin, Owen , Saade, Elie , Jacob, Jesse T. , Kršák, Martin , Huskins, W. Charles , Dhar, Sorabh , Shelburne, Samuel A. , Hill, Carol , Alby, Kevin , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , Tamma, Pranita D. , Kreiswirth, Barry N , Evans, Scott, Raterman, Erica L., Samuel, Tamika, Banerjee, Ritu , Cosgrove, Sara E. , Paterson, David L. , Mehigan, Maureen

Mayo Clinic

Clinical Infectious Diseases | March 4, 2026 | Volume: 83 | Issue: 1 | Pages: e27-e37

10.1093/cid/ciag160 | PMID 41795867 Get It

Abstract Background Ceftriaxone-resistant Escherichia coli infections are increasingly common, partially because of the emergence of E. coli sequence type 131 (ST131), including its subclade C2/H30Rx, which produce extended-spectrum β-lactamases. Methods A prospective cohort including 14 US sites, which enrolled monomicrobial ceftriaxone-resistant and susceptible E. coli bloodstream infection (BSI) cases in a 1:1 ratio, was used to compare ST131 versus non-ST131 E. coli BSI, with specific attention to E. coli ST131 C2/H30Rx. Desirability of outcome ranking was determined at 30 days after infection onset. Results This analysis included 282 patients with E. coli BSI; 43% (121/282) were E. coli ST131 and 23% (66/282) belonged to the C2/H30Rx subclade. Resistance to ceftriaxone was present in 79% (96/121) ST131, 86% (57/66) E. coli ST131 C2/H30Rx, and 27% (43/161) E. coli non-ST131. Compared to patients with non-ST131 E. coli BSI, patients with ST131 BSI were older (median 70 years, [Q1 62, Q3 76] years vs 65 years, [51, 74]; P = .005) and more often admitted from long-term care facilities (21/121 [17%] vs 7/161 [4%], P < .001). Overall and empiric carbapenem use was more frequent in the treatment of patients with ST131 BSI compared with non-ST131 BSI (overall 89/121 [74%] vs 50/161 [31%]; empiric: 58/121 [48%] vs 31/161 [19%], P < .001). Desirability of outcome ranking outcomes were similar between groups. Conclusions Most ceftriaxone-resistant E. coli from US patients with E. coli BSI belong to ST131, particularly E. coli ST131 C2/H30Rx, serving as an important driver of carbapenem use.
Interplay of Pulmonary Hypertension and the Effects of Panel‐Reactive Antibodies on Outcomes of Heart Transplant Recipients Bridged With Left Ventricular Assist Device
Khalil, Fouad , Asleh, Rabea , Mawer, Scott, Kim, Kathryn M., Regev, Ohad , Briasoulis, Alexandros, Alnsasra, Hilmi, Khalil, Fouad , Briasoulis, Alexandros , Alnsasra, Hilmi , Asleh, Rabea , Briasoulis, Αlexandros

Mayo Clinic

Journal of the American Heart Association | March 4, 2026 | Volume: 15 | Issue: 6 | Pages: No page available

10.1161/jaha.125.044572 | PMID 41778557 Get It

Background Pulmonary hypertension (PH) and sensitization adversely affect heart transplant outcomes. Although left ventricular assist devices may reduce PH, they can increase sensitization. We examined the impact of sensitization on heart transplant outcomes in left ventricular assist device‐bridged patients and whether precapillary PH modifies this effect. Methods Adults bridged to heart transplant with an left ventricular assist device between 2005 and 2020 were identified from the United Network for Organ Sharing database. Patients with available panel‐reactive antibody (PRA) and hemodynamic data were included. Associations between PRA and survival and treated rejection were analyzed. Results Among 2469 patients, 1053 had precapillary PH (pulmonary vascular resistance [PVR] >2 Wood units [WU]) and 1416 had PVR ≤2 WU. Elevated PRA (>10%) occurred in 566 patients (24.8% with PVR >2 WU; 21.5% with PVR ≤2 WU). Overall, PRA >10% was associated with increased mortality (adjusted hazard ratio [aHR], 1.28 [95% CI, 1.04–1.58], P =0.022), driven by patients with PVR >2 WU (aHR, 1.82 [95% CI, 1.34–2.50], P <0.001), with no association in those with PVR ≤2 WU (aHR, 0.99 [95% CI, 0.47–1.32], P =0.92). PRA >10% was also associated with treated rejection overall (adjusted odds ratio [aOR], 1.41 [95% CI, 1.09–1.82], P =0.008), confined to the PVR >2 WU group (aOR, 1.87 [95% CI, 1.26–2.76], P =0.002) and absent in the PVR ≤2 WU group (aOR, 1.13 [95% CI, 0.80–1.59], P =0.49). Conclusions Elevated PRA predicts worse outcomes in LVAD‐bridged transplant recepients with precapillary PH, but not in those without precapillary PH.
Dynamic investigator initiated enterprise (DIVINE) in prostate cancer: Randomized phase II trial of stereotactic body radiotherapy with or without short-course androgen deprivation and AR pathway inhibition in oligometastatic castration-sensitive prostate
Zarka, Jabra , Becker, Nicole A. , Gicobi, Joanina K. , Tabiim, Anthony, Heath, Elisabeth I. , Sartor, Alton Oliver, Park, Sean Sunghun, Ager, Casey, Andrews, Jack R. , Kase, Adam M. , YU, NATHAN Y., Vargas, C., Chaudhuri, Aadel A., Kim, Yohan, Cheville, John C. , Orme, Jacob J. , Tabiim, Anthony Jagri , Zarka, Jabra G , Tabiim, Anthony , Jang, Albert , Lucien, Fabrice , Childs, Daniel S. , Ager, Casey R. , Ballman, Karla V. , Chaudhuri, Aadel A.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps283 Get It

TPS283 Background: Emerging evidence suggests that metastasis-directed therapy (MDT) with stereotactic body radiotherapy (SBRT) can delay systemic therapy in oligometastatic castration-sensitive prostate cancer (omCSPC). However, the optimal timing of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (ARPI) initiation in this setting remains undefined. While deferred ADT following MDT may preserve quality of life, early short-course ADT/ARPI may eradicate micrometastatic disease and extend progression-free survival. Extracellular vesicles (EVs) carrying PSMA-positive prostate cancer (PC) signals and circulating tumor DNA (ctDNA) may serve as real-time biomarkers of MRD and treatment response. Methods: DIVINE [NCT06378866] is an open-label, phase II, randomized trial enrolling men with omCSPC defined by 1–5 metastases (≥1 extrapelvic) on conventional imaging (CT/MRI and bone scan) and testosterone >100 ng/dL. PSMA PET may be obtained for correlative purposes but does not determine eligibility. Participants (N = 220) are randomized 1:1 to: Arm A (Early systemic): SBRT plus 6 months of ADT + ARPI. Arm B (Deferred systemic): SBRT alone with observation, reserving systemic therapy until radiographic progression not amenable to further SBRT (mrPD). SBRT is delivered per institutional standard; repeat SBRT is allowed until lesions become non-addressable. The primary endpoint, modified radiographic progression-free survival (mrPFS), is the time from randomization to death or radiographic progression not amenable to further MDT, defined by PCWG3 (bone) and modified RECIST 1.1 (soft tissue) criteria on conventional imaging. Soft-tissue progression requires ≥ 20% increase in measurable disease or a new lesion; bone progression requires ≥ 2 new confirmed lesions. Secondary endpoints include OS, biochemical PFS, time to local and distant progression, and grade 3–5 adverse events during systemic therapy. Exploratory endpoints evaluate EV and ctDNA kinetics as MRD markers, correlation of PSMA-positive EV burden with outcomes, and duration of response after short-course ADT/ARPI. Correlative analyses will longitudinally quantify PSMA-positive EVs and ctDNA at baseline, on treatment, and at progression to define MRD dynamics and resistance patterns. The trial uses Pocock–Simon dynamic allocation by EV strata and metastatic burden to ensure balance across arms. The trial is open and actively enrolling across all Mayo Clinic sites; as of October 2025, 35 of the planned 220 patients have been accrued. Clinical trial information: NCT06378866 .
PARP1 and BRCA1/2 expression and overall survival in high risk of recurrence localized clear cell-type renal cell carcinoma.
Crispen, Paul L. , Kim, Donghyun, Araújo, Daniel Vilarim , George, Thomas J. , Milhem, Mohammed , Zakharia, Yousef

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 514-514

10.1200/jco.2026.44.7_suppl.514 Get It

514 Background: Poly(ADP-ribose) polymerase 1 (PARP1) senses single strand DNA damage and catalyzes repair mechanisms. PARP inhibitor (PARPi) suppresses PARP1 activity and promotes cell death in BRCA1 or BRCA2 mutated cancers that are homologous recombination repair deficient (HRD) via a phenomenon known as “synthetic lethality”. Utility of PARPi in HRD-negative (HRDn) cancers remain uncertain, although in a preclinical study overexpression—but not endogenous levels—of BRCA2 in mouse hybridoma cells led to HRD and increased sensitivity to DNA crosslinking agents, suggesting potential sensitization to PARPi. In renal cell carcinoma (RCC), HRD mutations are rare and the role of PARPi remains investigational. In this study, PARP1 and BRCA1/2 expression and overall survival (OS) in high risk of recurrence localized clear cell-type renal carcinoma (hrr-ccRCC) were explored. Methods: Batch-corrected bulk mRNA profile (RNA Seq V2 RSEM) and clinical data of HRDn stages II grade 4-only (n = 4) and III (n = 100) ccRCC from The Cancer Genome Atlas Pan-Cancer project were reviewed. Gene expression was classified “high” if mRNA level is higher than median, otherwise it was classified “low”. Survival analyses were Log-rank Kaplan-Meier. Group comparisons were two-tailed Mann-Whitney test. Results: In HRDn hrr-ccRCC (n = 104), BRCA1 and BRCA2 were upregulated by median fold change (mFC) of 1.6 and 3.7, respectively, whereas PARP1 was downregulated by mFC 0.8 compared to normal control (n = 72, all p < 0.0001). BRCA1 and BRCA2 levels were positively correlated (R 2 = 0.71). Median duration of follow-up for OS was 36.5 months (IQR 20.9-60.0). High BRCA2 (n = 54) was associated with superior OS compared to low BRCA2 (n = 50) with hazard ratio (HR) for death at 0.34 (95% CI 0.19-0.63, p = 0.0008). When high BRCA2 group was further stratified by PARP1 level, those with concomitant low PARP1 (n = 16) trended towards a superior OS compared to those with high PARP1 (n = 38) with HR 0.19 (95% CI 0.06-0.60, p = 0.067). Similarly, high BRCA1 (n = 53) was associated with superior OS compared to low BRCA1 (n = 51) with HR 0.53 (95% CI 0.29-0.96, p = 0.04). However, no differential OS was seen when high BRCA1 group was stratified by PARP1 level. No differential OS was seen when low BRCA1 or low BRCA2 groups were stratified by PARP1 level. Conclusions: In this retrospective analysis of HRDn hrr-ccRCC, high BRCA2 was associated with superior OS which was more pronounced with concomitant low PARP1 . High BRCA1 was also associated with superior OS, but PARP1 levels had no influence. The findings of this study may imply a potential therapeutic value of PARP1 suppression with PARPi by mimicking low PARP1 expression in treating HRDn hrr-ccRCC with BRCA2 overexpression. Further investigation is warranted.
Extracellular vesicles (EVs) and circulating tumor DNA (ctDNA) as potential biomarkers of response to 177 Lu-PSMA-617.
Kim, Yohan, Linford, Jessica , Huang, Minqi, Noori, Rubia, Muniz, Miguel, Zarka, Jabra , Heath, Elisabeth I. , Orme, Jacob J. , Chaudhuri, Aadel A., Sartor, Alton Oliver, Zarka, Jabra G , Jang, Albert , Chauhan, Pradeep S. , Greiner, Lilli , Childs, Daniel S. , Pachynski, Russell K. , Ledet, Elisa M. , Chaudhuri, Aadel A. , Lucien, Fabrice

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 214-214

10.1200/jco.2026.44.7_suppl.214 Get It

214 Background: 177 Lu-PSMA-617 (LuPSMA) has revolutionized care for patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC), but only half achieves PSA decline ≥50%. Biomarkers are urgently needed to improve pt selection. EVs and ctDNA released by cancer cells into the blood are emerging biomarkers to estimate overall tumor burden and capture tumor heterogeneity in mCRPC. Here, we analyzed pre-treatment plasma levels of tumor EVs and ctDNA in a pilot cohort of 35 pts with mCRPC treated with LuPSMA. Methods: Blood samples were collected pre-cycle 1 of LuPSMA at Tulane Cancer Center between 12/2018-1/2025. Plasma-derived small and large EVs were incubated with fluorescently conjugated antibodies and enumerated using nanoscale flow cytometry. ctDNA fraction was estimated from plasma cfDNA methylation WGS (∼10×) with ichorCNA. We also analyzed EVs from blood samples of male healthy donors (HD) and pts with localized prostate cancer (LPC) collected 1 day to 8 months after radical prostatectomy (post-RP) from 6/2020-8/2024 at Mayo Clinic as controls. Results: Median age at collection for 10 HD was 55 yrs and for 36 pts with LPC post-RP was 65 yrs. Median PSMA+ EV level was 2.0 x 10 6 /mL for post-RP and 1.4 x 10 6 /mL for HD. For 35 pts with mCRPC, 25 pts had complete data for analysis. Median PSMA+ EV level was 1.4 x 10 7 /mL, significantly higher than post-RP (p<0.001) and HD (p<0.001). At LuPSMA start, median age was 69 yrs (range 54-83), PSA was 82 ng/mL (range 0.8-503), median time from CRPC diagnosis to start was 50 months (range 6.9-285), median time from plasma collection to treatment initiation was 0.5 months (range 0-7.3). Median number of prior lines of life-extending therapy was 4 (range 1-11), including 100% androgen receptor pathway inhibitor and 75% docetaxel. Pts received median 4 cycles of LuPSMA. Median ctDNA fraction was 14.0% (range 0-51.1). Median time to reach nadir PSA for pts with any decline was 2.6 months. 15 pts (60%) achieved PSA40 (defined ≥40% decline in PSA from start to nadir) (range -99% to -42%) compared to 10 pts (40%) who did not (range -16% to rise), which predicted better median overall survival (OS) after LuPSMA start (40.7 v 6.0 months; HR 0.23, 95% CI, 0.07-0.71; p=0.0001). Pts were classified as LuPSMA responders using PSA40. Responders had a lower ratio of large to small PSMA+ EVs (0.30 v 0.53, p=0.0042) with an area under the receiver operating characteristic curve (AUC) of 0.83 (95% CI, 0.68-0.99), and a lower median ctDNA fraction (6.1% v 26.2%, p=0.0044) with an AUC of 0.83 (95% CI, 0.68-1.00). Incorporating both PSMA+ EV and ctDNA fraction together predicted PSA40 response with an AUC of 0.93 (95% CI, 0.84-1.00, p=0.0003). Conclusions: Using pre-LuPSMA plasma samples from a heavily pre-treated historical cohort, we integrated non-invasive liquid biopsy methods to successfully predict response to LuPSMA using PSA decline. Prospective validation is underway.
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2
Apostol, Adriana Ionelia , Gronwald, J., Cybulski, C., Kim, Raymond H. , Møller, P., Karlan, B., Bordeleau, Louise , Schrader, Intan , Cajal, Teresa Ramón y , Pal, Tuya, Eisen, Andrea, Singer, Christian F., Couch, Fergus J., Zakalik, Dana , Metcalfe, Kelly , Olopade, Olufunmilayo, Tung, Nadine, Fruscio, R, Foulkes, William D., Sun, P., Lubinski, J., Narod, Steven A., Sweet, Kevin , Elser, Christine , Panchal, Seema, Wiesner, Georgia L. , Armel, Susan, Steele, Linda, Serfas, Kim, Cullinane, Carey A., Reilly, Robert E., Mercer, L J, Dungan, Jeffrey R., Cohen, Stephanie, Neuhausen, Susan, Sun, Sophie, Blum, Joanne L., Stempa, Klaudia , Graham, Tracy Ann, Seca, Marta , Marchette, Martina Delle , Dell'Oro, Cristina, Alfonso, Rosa Moreno, Lopez, Consol, Cusco, Francesco, Karlan, Beth Y. , Schrader, Kasmintan A. , Eisen, Andrea , Apostol, Adriana I , Cybulski, Cezary , Karlan, Beth Y , Ramón Y Cajal, Teresa , Singer, Christian F , Couch, Fergus J. , Olopade, Olufunmilayo I , Tung, Nadine , Fruscio, Robert , Foulkes, William D , Aeilts, Amber M , Lubinski, Jan , Narod, Steven A , Kotsopoulos, Joanne , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Kim, Raymond H , Cybulski, Cezary , Møller, Pål , Pal, Tuya , Singer, Christian F. , Couch, Fergus J. , Olopade, Olufunmilayo I. , Tung, Nadine , Foulkes, William D. , Aeilts, Amber M. , Lubiński, Jan , Narod, Steven A. , Kotsopoulos, Joanne , Steele, Linda, Saal, Howard M. , Rayson, Daniel , Mercer, Leanne, Cohen, Stephanie, Neuhausen, Susan L, Senter, Leigha , Blum, Joanne Lorraine , Negri, Serena , Dell’Oro, Cristina, Inzoli, Alessandra , Alfonso, Rosa

Mayo Clinic

Journal of Clinical Oncology | February 28, 2026 | Volume: 44 | Issue: 10 | Pages: 883-892

10.1200/jco-25-01648 | PMID 41762747 Get It

PURPOSE BRCA carriers face high risks of developing both breast and ovarian/fallopian tube cancers (hereafter referred to as ovarian ). Among BRCA carriers with ovarian cancer, it is not clear whether the risk of breast cancer is sufficiently high that risk-reducing mastectomy should be offered. This study aimed to assess the risk of breast cancer BRCA carriers after a diagnosis of ovarian cancer. METHODS We included women with a pathogenic/likely pathogenic variant in BRCA1 or BRCA2 , a diagnosis of ovarian cancer, and no other cancer history and no risk-reducing bilateral mastectomy. Women were followed for incident breast cancer from the date of ovarian cancer diagnosis or the date of baseline questionnaire, whichever came last. The 5-, 10-, and 15-year cumulative risks of breast cancer were compared for women with ovarian cancer and an age-matched set of control women without ovarian cancer. RESULTS A total of 960 participants with ovarian cancer were identified (814 BRCA1 and 146 BRCA2 carriers). After a mean follow-up of 4.9 years, 41 women (4.3%) developed breast cancer, at a mean age at diagnosis of 57.5 years (range, 39-74). Actuarial cumulative breast cancer risks after ovarian cancer were 4.4%, 8.9%, and 11.5% at 5, 10, and 15 years, respectively. Only three breast cancer–related deaths occurred. Among 741 age-matched BRCA carriers without ovarian cancer, actuarial cumulative risks of breast cancer were 20.9%, 38.6%, and 47.2% at 5, 10, and 15 years, respectively. The hazard ratio for breast cancer, after an ovarian cancer diagnosis, compared with no ovarian cancer, was 0.18 ([95% CI, 0.12 to 0.27]; P < .0001). CONCLUSION After ovarian cancer, BRCA carriers have a relatively low risk of breast cancer. Risk-reducing mastectomy should not be recommended routinely, but might be considered for long-term survivors. Magnetic resonance imaging surveillance and/or mammography is a realistic alternative.